CD8A and neoplasm: By inhibiting CSF-1R, surufatinib could significantly decrease CSF-1R positive M2 TAM infiltration in tumor tissues, and increase the infiltration of M1-TAM (iNOS +) and CD8 + T cell, which result in enhancement of immune response (Zhou et al. 2017).